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Pulse wave velocity as a measure of arterial stiffness  
in patients with familial hypercholesterolemia:  
a systematic review and meta-analysis
Željko Reiner1, Luis E. Simental-Mendía2, Massimiliano Ruscica3, Niki Katsiki4, Maciej Banach5,6, 
Khalid Al Rasadi7, Tannaz Jamialahmadi8,9, Amirhossein Sahebkar10,11,12
A b s t r a c t
Introduction: The aim of this meta-analysis was to establish whether vascu-
lar pulse wave velocity (PWV) as a measure of arterial stiffness is changed 
in patients with familial hypercholesterolemia (FH).
Material and methods: Studies comparing PWV between patients with FH 
and controls were searched in PubMed-Medline, SCOPUS, Web of Science and 
Google Scholar databases (up to November 26, 2017). A  meta-analysis was 
conducted using Comprehensive Meta-Analysis V2 software. A random-effects 
model (using the DerSimonian-Laird method) and the generic inverse variance 
method were used to compensate for the heterogeneity of studies concerning 
demographic characteristics and differences in the studies’ design.
Results: This meta-analysis of 8 studies involving 317 patients with FH and 
244 non-FH individuals did not suggest a  significantly altered PWV in FH 
patients versus controls (weighted mean difference (WMD): 0.17 m/s, 95% 
confidence interval (CI): –0.31, 0.65, p = 0.489; I2 = 80.15%). The result was 
robust in the sensitivity analysis and its significance was not influenced 
after omitting each of the included studies from the meta-analysis. Subanal-
ysis of 6 of these studies which had data on intima-media thickness (IMT) 
indicated an increased IMT in FH patients when compared with controls 
(WMD = 0.03 mm, 95% CI: 0.003, 0.06, p = 0.034; I2 = 48.95%). However, the 
effect size was sensitive to some of the included studies.
Conclusions: This meta-analysis suggests that FH patients do not have sig-
nificantly altered PWV when compared with normocholesterolemic individu-
als. However, a subanalysis of studies in which IMT was measured indicated 
that IMT is increased in FH patients compared with controls. 
Key words: familial hypercholesterolemia, arterial stiffness, pulse wave ve-
locity, intima-media thickness.
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Introduction
Familial hypercholesterolemia (FH) is an autoso-
mal co-dominant inherited disorder of lipoprotein 
metabolism characterized by markedly elevated 
plasma LDL cholesterol (LDL-C) concentration from 
birth [1]. Therefore, patients with FH have an in-
creased risk of premature development of athero-
sclerosis, particularly atherosclerotic cardiovascu-
lar disease (ACVD) and/or coronary artery disease 
(CAD) [2]. Although heterozygous FH (HeFH) is one 
of the most common genetic disorders, and is as-
sociated with significant morbidity and mortality, 
it is very often underdiagnosed and massively un-
dertreated [3–6]. Therefore, recently registries of 
FH are being developed to assess gaps in care and 
improve disease management and outcomes [7] 
and attempts are in progress to identify secondary 
treatment targets other than LDL-C – which is the 
most important and primary target – to reduce the 
risk of ACVD in these patients [8–11]. The preva-
lence of FH in the general population is estimat-
ed at around 1 in 200–500, while there are data 
indicating that in patients with established CAD, 
the prevalence of potential FH seems to be even 
8.3%; 7.5% in men and 11.1% in women [12]. FH 
is, in more than 90% of cases, caused by loss-of-
function (LOF) mutations in the gene encoding 
LDL receptor (LDLR), which have as a consequence 
a  decreased cellular uptake of LDL particles and 
therefore significantly elevated plasma LDL-C con-
centrations [13]. Currently more than 1700 such 
mutations have been documented [14, 15]. Howev-
er, mutations of other genes related to apolipopro-
tein B that affect the LDLR-binding domain of apo-
lipoprotein B as the most important apolipoprotein 
for LDL particles’ uptake, and the gain-of-function 
(GOF) mutations of proprotein convertase subtil-
isin/kexin9 (PCSK9) – a serine protease essential 
for LDLR recycling – have also been identified and 
they result in an identical phenotype as patients 
with LDLR mutations [2, 16].
Atherosclerosis of the arteries causes loss of 
elasticity and increased rigidity, resulting in in-
creased velocity of pulse waves since they travel 
faster in stiff arteries. Arterial stiffness is a robust 
predictor of all-cause and CVD mortality, fatal 
and non-fatal coronary events and fatal strokes 
[17–20]. As pulse wave velocity (PWV) is the most 
widely used and validated technique for estimat-
ing arterial stiffness, high PWV represents an early 
sign of arteriosclerosis/atherosclerosis [21].
Intima-media thickness (IMT), particularly ca-
rotid IMT, is recognized as a surrogate marker of 
atherosclerosis, given its predictive association 
with CAD [22]. Therefore, it was considered that 
the measurement of carotid IMT and/or screening 
for atherosclerotic plaques by carotid artery ultra-
sound can add information beyond assessment 
of traditional risk factors in asymptomatic adults 
at moderate CV risk [23]. However, the evidence 
that measurement of common carotid IMT can 
improve the risk prediction of CVD events is in-
consistent [24]. Even the position paper from the 
European Society of Cardiology Working Group on 
peripheral circulation stated that it is still unclear 
whether a  specific vascular biomarker (including 
IMT) is clearly superior and that a  prospective 
study in which all vascular biomarkers are mea-
sured is still lacking [25].
The aim of this meta-analysis was to establish 
whether PWV as a  marker of arterial stiffness is 
changed in patients with FH compared with non-
FH individuals. The secondary goal of this meta- 
analysis was to determine whether IMT is different 
in FH patients compared with non-FH subjects.
Material and methods
Search strategy
The study was designed according to the 
guidelines for systematic reviews and me-
ta-analysis, the PRISMA statement [26]. SCOPUS, 
PubMed-Medline, Google Scholar and ISI Web 
of Science databases were searched using the 
following search terms in titles and abstracts: 
(“familial hypercholesterolemia” OR “familial hy-
percholesterolaemia” OR “familial hypercholester-
olemic” OR “familial hypercholesterolaemic”) AND 
(“pulse wave velocity” OR PWV OR aPWV OR cPWV 
OR fPWV OR cfPWV OR “arterial distensibility” OR 
“vascular distensibility” OR “aortic distensibility” 
OR “arterial stiffness” OR “arterial stiffening” OR 
“vascular stiffness” OR “vascular stiffening” OR 
“aortic stiffness” OR “aortic stiffening” OR “arteri-
al compliance” OR “vascular compliance” OR “aor-
tic compliance”). The wild-card term “*” was used 
to increase the sensitivity of the search strategy. 
No language restriction was used in the literature 
search. The literature was searched from incep-
tion to November 26, 2017.
Study selection
Original studies were included if they met the 
following inclusion criteria: (i) an observational 
study (i.e., a case-control, cross-sectional or cohort 
design), (ii) comparison of vascular PWV between 
patients with FH and controls without FH, and 
(iii) presentation of information on PWV in each 
group. Studies with undefined control groups, du-
plicate or overlapped populations with a previous 
study, or reported PWV values in a  single group 
were excluded.
Data extraction
The following data were basically needed: 
1) first author’s name, 2) year of publication, 
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3) study location, 4) age and gender of patients, 
5) number of patients (by gender if described), 
6) study design, 7) type of FH (homozygous or 
heterozygous), 8) diagnostic criteria to define FH, 
9) IMT values, 10) type of vessel on which PWV 
was measured, and 11) PWV values.
Quality assessment
Methodological quality of the included studies 
was assessed using the Newcastle-Ottawa Scale 
(NOS) [27]. In this scale, three aspects of each el-
igible study are evaluated: (i) the selection of the 
studied patients (4 items), (ii) the comparability of 
the studied populations (one item) and (iii) the as-
certainment of the exposure (3 items) in case-con-
trol studies or outcome of interest in cohort stud-
ies. A  study can be awarded a maximum of one 
point for each item in the selection and exposure 
categories, whilst the comparability item can re-
ceive a maximum of two points.
Quantitative data synthesis
A meta-analysis was conducted using Compre-
hensive Meta-Analysis (CMA) V2 software [28]. All 
PWV values were collated in m/s. Standard devi-
ation (SD) of the mean difference was calculated 
using the following formula: 
Spooled = 
(n1 – 1)S1
2 + (n2 – 1)S2
2
n1 + n2 – 2
Where n1 and n2 are population sizes of FH and 
control groups while S1 and S2 represent SD val-
ues of the respective groups.
If the outcome measures were reported in me-
dian and inter-quartile range, mean and SD values 
were estimated using the method as described by 
Wan et al. [29]. Where standard error of the mean 
(SEM) was only reported, SD was estimated using 
the following formula: SD = SEM × sqrt (n), where 
n is the number of subjects.
A random-effects model (using the DerSimoni-
an-Laird method) and the generic inverse variance 
method were used to compensate for the hetero-
geneity of studies in terms of demographic charac-
teristics of studied populations and also differences 
in the study design. Heterogeneity was quantita-
tively assessed using the I2 index. Effect sizes were 
expressed as weighted mean difference (WMD) 
and 95% confidence interval (CI). In order to eval-
uate the influence of each study on the overall ef-
fect size, sensitivity analysis was conducted using 
the leave-one-out method, i.e. removing one study 
each time and repeating the analysis [30–32].
Publication bias
Potential publication bias was explored using 
visual inspection of Begg’s funnel plot asymmetry, 
Begg’s rank correlation test and Egger’s weighted 
regression test. The Duval & Tweedie “trim and 
fill” method was used to adjust the analysis for 
the effects of publication bias [33].
Results
Characteristics of the included studies
Initially, 177 published studies were identified 
following a multiple database search. After screen-
ing of titles and abstracts and removing non-origi-
nal studies (n = 69) and studies that did not meet 
the inclusion criteria (n = 91), 17 full text articles 
were carefully assessed and reviewed for eligibil-
ity. Of these, 11 clinical trials were excluded for 
not measuring PWV (n = 9), because they were 
performed in a non-FH population (n = 1), or were 
uncontrolled studies (n = 1), thus leaving 8 eligible 
articles for the present meta-analysis (Figure 1).
A  total of 317 patients with FH and 244 nor-
mocholesterolemic controls were included in this 
meta-analysis. Included studies were published 
between 2007 and 2016. FH populations from the 
following countries were included: Brazil, Greece, 
Italy, Russia, Poland, Taiwan and the UK. There 
were 4 studies performed on heterozygous and 
4 on unspecified type of FH patients. Study de-
sign of selected studies was cross-sectional and 
case-control.
Concerning the diagnosis of FH, four studies 
used gene mutation analysis, two studies used 
the Simon Broome criteria, one study used the 
Dutch Lipid Clinic Network criteria, and another 
study used the U.S.MEDPED criteria (Table I).
PWV assay methods
Different methods were used to measure the 
PWV. In this regard, one study used a VP-1000 de-
vice (Colin Corporation, Komaki, Japan) to measure 
the brachial-ankle PWV. One study determined the 
PWV with a  Vicorder device (Skidmore medical, 
Bristol, UK) while another study used echo-track-
ing software (Aloka Prosound Alpha7, Hitachi-Alo-
ka, Tokyo, Japan) and a 14 MHz linear-type probe 
to assess the PWV. Two studies measured the 
PWV using the echo-tracking method with Aloka 
SSD-Alpha 10-Miro and the automatic system of 
ultrasound vascular evaluation. Furthermore, two 
other studies evaluated the PWV with a Compli-
or device (Colson, Garges les Gonesses, France). 
Finally, Vlahos et al. [34] used echo-Doppler ultra-
sound (Ultrasound ATL, HDI 5000, Bothell, WA) to 
assess the PWV.
Quality assessment of the included studies
Most of the studies exhibited sufficient in-
formation concerning definition of cases and 
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controls, but there was a lack of information re-
garding representativeness of the cases and se-
lection of controls. Other parameters for quality 
assessment of the included studies are shown in 
Table II.
Comparison of PWV between patients with 
FH and controls
Overall, 8 studies compared PWV between pa-
tients with FH and normocholesterolemic controls. 
The meta-analysis did not suggest a significantly 
altered PWV in FH patients versus controls (WMD 
= 0.17 m/s, 95% CI: –0.31, 0.65, p = 0.489; I2 = 
80.15%) (Figure 2). This result was robust in the 
sensitivity analysis and its significance was not 
influenced after omitting each of the included 
studies from the meta-analysis (Figure 2). In the 
subgroup analysis, there was no significant dif-
ference between subgroups of studies in patients 
≤ 20 years (WMD = 0.41 m/s, 95% CI: –0.95, 1.76, 
p = 0.557; I2 = 94.41%) and > 20 years (WMD 
= 0.07 m/s, 95% CI: –0.39, 0.53, p = 0.758; I2 = 
62.72%) (between-group p = 0.647). Likewise, the 
estimated effect size was not significantly differ-
ent between patients with FH and controls in the 
subgroup of studies in confirmed HeFH patients 
(WMD = 0.40 m/s, 95% CI: –0.29, 1.09, p = 0.253; 
I2 = 83.78%). 
Among the included studies, 6 studies also as-
sessed IMT. Subanalysis of these studies indicated 
an increased IMT in FH patients when compared 
with controls (WMD = 0.03 mm, 95% CI: 0.003, 
0.06, p = 0.034; I2 = 48.95%) (Figure 3). However, 
the effect size was sensitive to some of the includ-
ed studies, as shown in Figure 3.
Publication bias
There was no evidence of publication bias ac-
cording to the results of Egger’s linear regression 
(intercept = –1.32, standard error = 2.16, 95% CI: 
–6.61, 3.97, t = 0.61, df = 6, two-tailed p = 0.565) 
and Begg’s rank correlation tests (Kendall’s t with 
continuity correction = –0.04, z = 0.12, two-tailed 
p = 0.902; Figure 4). The funnel plot of the study 
standard error by effect size (WMD) was slightly 
asymmetric. This asymmetry was addressed by 
imputing one potentially missing study using the 
“trim and fill” method. After imputation, the effect 
size was changed to 0.23 (95% CI: –0.25, 0.71) 
and remained non-significant.
Discussion
To our knowledge this is the first meta-analysis 
evaluating PWV as a measure of arterial stiffness 
in patients with FH. The results of this meta-anal-
ysis suggest that FH patients do not have signifi-
cantly altered PWV compared with controls. How-
ever, a  subanalysis of studies in which IMT was 
measured indicates that IMT is increased in FH 
patients when compared with controls. 
This meta-analysis did not include the most re-
cently published results of a study performed on 
245 patients with FH, which suggested a different 
conclusion, i.e. that arterial stiffness assessed by 
the PWV was significantly associated with the 
presence of coronary heart disease in patients 
with FH [35]. Nevertheless, there was no compar-
ison with normocholesterolemic controls in the 
study published by Tada et al. [35]. Another recent 
study on 66 patients with FH and their 57 first-de-
gree relatives without FH demonstrated that treat-
Figure 1. Flow chart of the number of studies identified and included in the meta-analysis
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ment-naïve FH patients had stiffer carotid arteries 
than their relatives but showed no difference in 
aortic stiffness [36]. Furthermore, in another rela-
tively small study (81 FH patients compared with 
normal subjects), these markers poorly correlat-
ed among each other in univariate analysis and 
this correlation disappeared after adjustment for 
confounders [37]. Other authors could also not 
find any significant difference in arterial stiff-
ness (assessed by pulse-wave analysis using the 
echo-tracking method and photoplethysmograph-
ic pulse waveform analysis) between patients 
with and without FH [38].
There are reports that arterial stiffness mea-
sured by PWV, but not IMT, is increased in untreat-
ed hypercholesterolemic children (almost half of 
them had FH) when compared with age- and sex-
matched controls [39]. When mentioning studies 
in children with FH, a relatively recent study found 
no significant difference either in arterial stiffness 
or in carotid IMT between HeFH children and their 
sex- and age-matched controls without FH [34]. 
However, a very recent study showed that in HeFH 
children carotid IMT was significantly greater at 
baseline when compared with unaffected siblings 
[40]. The same study indicated that treatment with 
rosuvastatin for two years resulted in significantly 
less progression of increased carotid IMT in chil-
dren with HeFH than untreated unaffected sib-
lings and, as a result, no difference in carotid IMT 
could be detected between these two groups after 
2 years. This confirmed earlier studies indicating 
that the difference in carotid IMT between children 
with FH and their unaffected siblings may be sig-
nificant as early as at 8 years of age, that long-term 
statin treatment (lasting 10 years) initiated during 
childhood in patients with FH was associated with 
normalization of carotid IMT progression, and that 
earlier statin initiation was associated with thinner 
carotid IMT at follow-up [41, 42].
It could be supposed that long-lasting lipid-low-
ering treatment might improve PWV in adult pa-
tients with FH. Indeed, it was shown that 1 year of 
cholesterol lowering therapy with statins (simvas-
tatin, atorvastatin 40–80 mg day) in FH patients 
can decrease the wall stiffness in the carotid and 
femoral arterial wall and thickness in the common 
carotid artery [43].
It is well known that adult patients with FH are 
not at moderate but either at high or at very high 
ACVD risk, so there is no point in screening them 
by carotid IMT measurement in order to improve 
their risk assessment [44–46]. Therefore, the find-
ing of this meta-analysis, that IMT is increased in 
FH patients compared with controls, is absolutely 
logical and fits well with the common knowledge 
about FH. Moreover, a recent study proved that FH 
patients with a monogenic cause of the disease 
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have a greater carotid IMT and more severe cor-
onary preclinical atherosclerosis than those with 
a polygenic etiology [47].
Only one meta-analysis which investigated IMT 
in FH patients compared to normolipidemic con-
trols has been published, 7 years ago. In this meta- 
analysis, in FH patients both carotid and femoral 
IMT values were higher [48]. Nevertheless, this 
meta-analysis was aimed more at proving that 
treatment with statins can improve arterial func-
tion and structure in FH patients in a  treatment 
intensity-related manner. In this context it is in-
teresting to mention that one study proved that 
not only carotid IMT but also carotid plaques did 
not differ between long-term statin-treated HeFH 
patients and healthy controls, suggesting that 
long-term treatment in these patients can reduce 
carotid atherosclerosis to the degree of a healthy 
Study name    Statistics for each study   Difference in means and 95% CI 
 Difference  Standard Variance Lower Upper Z-value P-value
 in means  error    limit  limit  
Cheng et al., 2017 0.609 0.822 0.676 –1.002 2.220 0.741 0.459  
Ellins et al., 2016 –0.500 0.257 0.066 –1.003 0.003 –1.948 0.051  
Ershova et al., 2016 0.300 0.213 0.046 –0.118 0.718 1.406 0.160  
Lewandowski et al., 2014 –1.500 1.160 1.345 –3.773 0.773 –1.294 0.196  
Martinez et al., 2008 0.700 0.290 0.084 0.132 1.268 2.415 0.016 
Riggio et al., 2010 1.090 0.214 0.046 0.671 1.509 5.104 < 0.001 
Vlahos et al., 2014 –0.290 0.247 0.061 –0.773 0.193 –1.176 0.240 
Walus-Miarka et al., 2013 –0.100 0.282 0.079 –0.652 0.452 –0.355 0.723  
 0.169 0.244 0.060 –0.310 0.648 0.691 0.489 
Study name   Statistics for study removed   Difference in means (95% CI) 
 Point  Standard Variance Lower Upper Z-value P-value with study removed
   error    limit  limit  
Cheng et al., 2017 0.139 0.257 0.066 –0.365 0.643 0.541 0.588 
Ellins et al., 2016 0.294 0.248 0.061 –0.192 0.779 1.185 0.236 
Ershova et al., 2016 0.134 0.301 0.091 –0.456 0.724 0.444 0.657 
Lewandowski et al., 2014 0.230 0.245 0.060 –0.250 0.711 0.939 0.348 
Martinez et al., 2008 0.077 0.274 0.075 –0.460 0.614 0.280 0.779 
Riggio et al., 2010 0.005 0.198 0.039 –0.382 0.393 0.028 0.978 
Vlahos et al., 2014 0.249 0.270 0.073 –0.279 0.778 0.925 0.355 
Walus-Miarka et al., 2013 0.209 0.280 0.078 –0.339 0.758 0.747 0.455 
 0.169 0.244 0.060 –0.310 0.648 0.691 0489 
Figure 2. Forest plot displaying weighted mean difference and 95% confidence intervals of pulse wave velocity 
between patients with familial hypercholesterolemia and unaffected controls. Lower plot shows leave-one-out 
sensitivity analysis
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Study name    Statistics for each study   Difference in means and 95% CI 
 Difference  Standard Variance Lower Upper Z-value P-value
 in means  error    limit  limit  
Cheng et al., 2017 0.420 0.221 0.049 –0.013 0.853 1.902 0.057  
Ershova et al., 2016 0.040 0.026 0.001 –0.012 0.092 1.521 0.128 
Martinez et al., 2008 0.060 0.031 0.001 –0.001 0.121 1.930 0.054 
Riggio et al., 2010 0.000 0.027 0.001 –0.053 0.053 0000 1.000 
Vlahos et al., 2014 0.010 0.011 0.000 –0.011 0.031 0.939 0.348 
Walus-Miarka et al., 2013 0.070 0.029 0.001 0.012 0.128 2.373 0.018 
 0.033 0.015 0.000 0.003 0.063 2.124 0.034  
Study name   Statistics for study removed   Difference in means (95% CI) 
 Point  Standard Variance Lower Upper Z-value P-value with study removed
   error    limit  limit  
Cheng et al., 2017 0.029 0.013 0.000 0.003 0.054 2.188 0.029  
Ershova et al., 2016 0.033 0.019 0.000 –0.005 0.071 1.723 0.085  
Martinez et al., 2008 0.028 0.017 0.000 –0.005 0.062 1.655 0.098 
Riggio et al., 2010 0.042 0.019 0.000 0.005 0.079 2.217 0.027 
Vlahos et al., 2014 0.044 0.019 0.000 0.006 0.082 2.280 0.023 
Walus-Miarka et al., 2013 0.025 0.015 0.000 –0.006 0.055 1.590 0.112 
 0.033 0.015 0.000 0.003 0.063 2.124 0.034 
Figure 3. Forest plot displaying weighted mean difference and 95% confidence intervals of intima-media thickness 
between patients with familial hypercholesterolemia and unaffected controls. Lower plot shows leave-one-out 
sensitivity analysis
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population [49]. These findings strongly suggest 
that measuring carotid IMT during follow-up 
of statin-treated FH patients has limited value 
[49]. When mentioning measurement of carotid 
plaques, a very recent study on 225 patients with 
FH showed that carotid plaque score determined 
by carotid ultrasonography may provide superior 
risk stratification in patients with FH compared 
with carotid IMT [50].
Our meta-analysis has several limitations. Dif-
ferent scores for FH diagnosis as well as different 
methods for PWV estimation were used in different 
studies included in the present meta-analysis and 
there was a lack of information about the duration 
of lipid-lowering therapy and type of treatment 
(i.e. statin type and dose, statin and ezetimibe 
combined treatment, apheresis, PCSK9 inhibitors). 
These data are important as statins may improve 
PWV and arterial stiffness [51, 52] while the infor-
mation on novel lipid-lowering therapies including 
PCSK9 inhibitors is scant. In this context, PCSK9 
inhibitors have been suggested to have additional 
effects [53, 54] beyond their well-known lipid-low-
ering properties [55, 56]. Similarly, antihyperten-
sive drugs may differentially affect PWV based on 
the type and duration of treatment [57–60].
In conclusion, the present meta-analysis sug-
gests that FH patients do not have significantly al-
tered PWV as a measure of arterial stiffness when 
compared with normocholesterolemic controls. 
However, a subanalysis of studies, in which IMT was 
measured, indicates that IMT is increased in FH pa-
tients when compared with controls. Given the prev-
alence and burden of FH [61–63], additional studies 
are suggested to assess IMT as a risk predictor in 
FH individuals. Obviously, larger studies evaluating 
PWV in FH patients compared with controls in order 
to elucidate the impact of FH on arterial stiffness as 
measured by PWV, if any, are needed.
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